Home > Back to Publisher > Report Information

Apoptotic Therapeutics in Oncology - Where to Commercialize?

BioSeeker Group AB
November 30, 2009
803 Pages - SKU: BIOS2538647

Abstract Table of Contents Related Reports

This report comprises defined and up to date development strategies for 171 apoptotic drugs (519 projects) within the portfolio of 125 investigators, from Ceased to Pre-registration. The report extensively analyses 146 identified targets of apoptotic drugs, organized into 120 drug target profiles, and assesses them in 53 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any apoptotic drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents: 4.1 List of Figures; 4.2 List of Tables
5 Introduction: 5.1 The Scope of this Report; 5.2 Definitions; 5.3 Abbreviations
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment: 6.1 Drug Repositioning in Oncology; 6.2 Introduction to Apoptotic Therapeutic Targets in Oncology; 6.3 The Cancer Genome Project and Apoptotic Therapeutic Targets in Oncology; 6.4 Structure-based Drug Design in Apoptotic Therapeutics is Stimulated by Available Structure Data on Biological Targets; 6.5 Target-Target Interactions among Identified Apoptotic Therapeutics Targets in Oncology; 6.6 The Drug-Target Interactome; 6.7 Protein Expression Levels of Identified Apoptotic Therapeutic Targets in Oncology; 6.8 Pathway Analysis of Cancer Apoptotic Therapeutic Targets
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Apoptotic Therapeutic Pipeline?: 7.1 Terminated Drug Target Profiles of Cancer Apoptotic Drugs; 7.2 Pre-Registration: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology; 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology; 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology; 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology; 7.6 Preclinical Development: New and Unique Drug Target Profiles of Apoptotic Therapeutics in Oncology; 7.7 Development Profiles of All Apoptotic Drugs in Oncology
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Drugs in Oncology by Compound Type: 8.1 Small Molecules; 8.2 Peptide/Protein Drugs; 8.3 Antibodies and Antibody-like Structures; 8.4 Nucleic Acid Therapies; 8.5 Gene Therapy; 8.6 Drug Delivery and Nanotechnology; 8.7 The Competition Through Close Mechanistic Approximation of Apoptotic Cancer Therapeutics; 8.8 Compound Strategies based on Sub-Cellular Localization of Apoptotic Drug Targets in Oncology
9 Selecting Cancer Indications for Apoptotic Therapeutics: 9.1 Acute Lymphocytic Leukemia; 9.2 Acute Myelogenous Leukemia; 9.3 Adrenal Cancer; 9.4 B-cell Lymphoma; 9.5 Basal Cell Cancer; 9.6 Biliary Cancer; 9.7 Bladder Cancer; 9.8 Bone Cancer; 9.9 Brain Cancer; 9.10 Breast Cancer; 9.11 Carcinoid; 9.12 Cervical Cancer; 9.13 Chronic Lymphocytic Leukemia; 9.14 Chronic Myelogenous Leukemia; 9.15 Colorectal Cancer; 9.16 Endometrial Cancer; 9.17 Ewing's Sarcoma; 9.18 Fallopian Tube Cancer; 9.19 Fibro Sarcoma; 9.20 Gastrointestinal Cancer (general); 9.21 Gastrointestinal Stomach Cancer; 9.22 Gastrointestinal Stromal Cancer; 9.23 Head and Neck Cancer; 9.24 Hodgkin's Lymphoma; 9.25 Leiomyo Sarcoma; 9.26 Leukemia (general); 9.27 Lipo Sarcoma; 9.28 Liver Cancer; 9.29 Lung Cancer (general); 9.30 Lymphoma (general); 9.31 Melanoma; 9.32 Mesothelioma; 9.33 Myelodysplastic Syndrome; 9.34 Myeloma; 9.35 Nasopharyngeal Cancer; 9.36 non-Hodgkin's Lymphoma; 9.37 Non-Small Cell Lung Cancer; 9.38 Oesophageal Cancer; 9.39 Osteo Sarcoma; 9.40 Ovarian Cancer; 9.41 Pancreatic Cancer; 9.42 Peritoneal Cancer; 9.43 Prostate Cancer; 9.44 Renal Cancer; 9.45 Sarcoma (general); 9.46 Small Cell Lung Cancer; 9.47 Soft Tissue Sarcoma; 9.48 Squamous Cell Cancer; 9.49 T-cell Lymphoma; 9.50 Testicular Cancer; 9.51 Thymoma Cancer; 9.52 Thyroid Cancer; 9.53 Unspecified Cancer Indication
10 Portfolio Planning: Competitive Benchmarking of Apoptotic Cancer Therapeutic Pipeline by Investigator: 10.1 Abbott; 10.2 AbGenomics; 10.3 Access; 10.4 Advanced Life Sciences; 10.5 AEgera; 10.6 Aeterna Zentaris; 10.7 Aida Pharmaceuticals; 10.8 Ambrilia Biopharma; 10.9 Amgen; 10.10 Anadys Pharmaceuticals; 10.11 Anavex Life Sciences; 10.12 Antisoma; 10.13 Aphios; 10.14 Apogenix; 10.15 ApopLogic Pharmaceuticals; 10.16 Arno Therapeutics; 10.17 ArQule; 10.18 Ascenta Therapeutics; 10.19 Attenuon; 10.20 Basilea Pharmaceutica; 10.21 Bayer; 10.22 BioAxone; 10.23 Biogen Idec; 10.24 BioInvent; 10.25 BioLineRx; 10.26 Bionovo; 10.27 BioVex; 10.28 Cancer Research Technology; 10.29 Cephalon; 10.30 ChemoCentryx; 10.31 Chlorogen; 10.32 Chroma Therapeutics; 10.33 Cleveland BioLabs; 10.34 CombinatoRx; 10.35 Coronado Biosciences; 10.36 Critical Outcome Technologies; 10.37 Curis; 10.38 Cyclacel; 10.39 Cylene Pharmaceuticals; 10.40 Cytochroma; 10.41 Daewoong; 10.42 Daiichi Sankyo; 10.43 Dainippon Sumitomo Pharma; 10.44 Eisai; 10.45 Eleos; 10.46 Eli Lilly; 10.47 EntreMed; 10.48 Enzon; 10.49 EpiCept; 10.50 Exelixis; 10.51 Genentech; 10.52 Genta; 10.53 Genzyme; 10.54 Gerolymatos; 10.55 Geron; 10.56 GlycoGenesys; 10.57 GPC Biotech; 10.58 Hoffmann-La Roche; 10.59 Hollis-Eden Pharmaceuticals; 10.60 Human Genome Sciences; 10.61 Idera Pharmaceuticals; 10.62 Infinity Pharmaceuticals; 10.63 InNexus Biotechnology; 10.64 Insmed; 10.65 Intradigm; 10.66 Introgen Therapeutics; 10.67 Isis Pharmaceuticals; 10.68 ISU ABXIS; 10.69 Johnson & Johnson; 10.70 Kalypsys; 10.71 Keryx Biopharmaceuticals; 10.72 Kyowa Hakko Kirin; 10.73 Lorus Therapeutics; 10.74 Medisyn Technologies; 10.75 Merck & Co; 10.76 MethylGene; 10.77 NeoPharm; 10.78 NIH - The US National Institute of Health; 10.79 Nippon Shinyaku; 10.80 Non-industrial Sources; 10.81 Novacea; 10.82 Novartis; 10.83 Novelix; 10.84 Novogen; 10.85 Onconova; 10.86 OSI Pharmaceuticals; 10.87 OXiGENE; 10.88 PanaGin; 10.89 Patrys; 10.90 Pfizer; 10.91 Pharmacyclics; 10.92 PharmaMar; 10.93 Pharminox; 10.94 Phytomedics; 10.95 Pierre Fabre; 10.96 QLT; 10.97 Reata Pharmaceuticals; 10.98 Regulon; 10.99 Rosetta Genomics; 10.100 Sanofi-Aventis; 10.101 Santaris Pharma; 10.102 Semafore Pharmaceuticals; 10.103 Senesco Technologies; 10.104 Sigma-Tau; 10.105 SRI International; 10.106 SuperGen; 10.107 Switch Pharma; 10.108 Symbiotec; 10.109 Taxolog; 10.110 Telik; 10.111 Thallion Pharmaceuticals; 10.112 Tigris Pharmaceuticals; 10.113 TopoTarget; 10.114 Tracon Pharmaceuticals; 10.115 Trubion; 10.116 UMN Pharma; 10.117 ValiRx; 10.118 Vascular Biogenics; 10.119 Vertex Pharmaceuticals; 10.120 VioQuest; 10.121 Viragen; 10.122 Viralytics; 10.123 ViroTarg; 10.124 VM Discovery; 10.125 ZymoGenetics; 11 Disclaimer; 12 Drug Index; 13 Company Index
4.1 List of Figures: Figure 1: Visualization of Target-Target Interactions among Apoptotic Drug Targets in Oncology; Figure 2: The Drug-Protein Interactome of Apoptotic Drugs -Large Clusters; Figure 3: The Drug-Protein Interactome of Apoptotic Drugs - Small Clusters; Figure 4: Head-to-Head Targeting Interactome of Apoptotic Drugs; Figure 5: Distribution of Compound Types among Apoptotic Drugs in Oncology; Figure 6: Primary Sub-cellular Localization of Drug Targets
4.2 List of Tables: Table 1: Head to Head Competition among Apoptopic Drugs in Oncology; Table 2: Overall Breakdown of the Included Apoptotic Pipeline by Cancer Indication and Stage of Development; Table 3: Overview of Drug Target Profile Themes; Table 4: Terminally Ceased Therapeutic Apoptotic Targets in Oncology; Table 5: Drug Targets of Apoptotic Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census; Table 6: Identity of Apoptotic Drug Targets with Available Biological Structures; Table 7: Number of Target-Target Interactions among Apoptotic Drug Targets in Oncology; Table 8: Drug-Protein Interactome Clusters of Apoptotic Drugs in Oncology; Table 9: Apoptotic Drug Targets with Available Protein Expression Profiles; Table 10: Pathway Summary; Table 11: Drug Targets without any Identified Assigned Pathways; Table 12: Pathway Profiles According to BioCarta of Apoptotic Drug Targets in Oncology; Table 13: Pathway Profiles According to KEGG of Apoptotic Drug Targets in Oncology; Table 14: Pathway Profiles According to NetPath of Apoptotic Drug Targets in Oncology; Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness; Table 16: Top Competitive Apoptotic Target Profiles in Oncology; Table 17: Terminated Drug Target Strategies of Apoptotic Drugs in Oncology; Table 18 New and Unique Apoptotic Target Strategies in Cancer Currently in Pre-Registration; Table 19: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase III Clinical Development 290; Table 20: New and Unique Apoptotic Target Strategies in Cancer Currently in Phase II Clinical Development . 291; Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Apoptotic Drugs in Oncology; Table 22 New and Unique Apoptotic Target Strategies in Cancer Currently in Phase I Clinical Development; Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Apoptotic Drugs in Oncology; Table 24: New and Unique Apoptotic Target Strategies in Oncology Currently in Preclinical Development; Table 25: The Competition Through Close Mechanistic Approximation Between Preclinical Apoptotic Drugs in Oncology; Table 26: The Progression, Maturity and Competitive Comparison of Apoptotic Drug Target Profiles in Cancer Drug Development; Table 27: Overview of Compound Strategy Competition Among Apoptotic Drugs in Oncology; Table 28: Overview of the Competitive Landscape of Apoptotic Small Molecular Drugs in Oncology; Table 29: The Competition Through Close Mechanistic Approximation between Apoptotic Small Molecule Drugs; in Oncology; Table 30: Competitive Comparison of Target Profiles of Apoptotic Small Molecule Drugs in Oncology; Table 31: Overview of the Competitive Landscape of Peptide Based Apoptotic Drugs in Oncology; Table 32: The Competition Through Close Mechanistic Approximation between Apoptotic Peptide Based Drugs in Oncology; Table 33: Competitive Comparison of Target Profiles of Apoptotic Peptide Based Drugs in Oncology; Table 34: Overview of the Competitive Landscape of Apoptotic Protein Based Drugs in Oncology; Table 35: The Competition Through Close Mechanistic Approximation between Apoptotic Protein Based Drugs in Oncology; Table 36: Competitive Comparison of Apoptotic Protein Based Drugs in Oncology; Table 37: Overview of the Competitive Landscape of Apoptotic Antibody Drugs in Oncology; Table 38: The Competition Through Close Mechanistic Approximation between Apoptotic Antibody Drugs in; Oncology; Table 39: Competitive Comparison of Target Profiles of Apoptotic Antibody Drugs in Oncology; Table 40: Overview of the Competitive Landscape of Apoptotic Nucleic Acid Therapy Drugs in Oncology; Table 41: The Competition Through Close Mechanistic Approximation between Apoptotic Nucleic Acid Therapy; Drugs in Oncology; Table 42: Competitive Comparison of Target Profiles of Apoptotic Nucleic Acid Drugs in Oncology; Table 43: Vectors in Gene Therapy; Table 44: Overview of the Competitive Landscape of Apoptotic Gene Therapy Drugs in Oncology; Table 45: The Competition Through Close Mechanistic Approximation between Apoptotic Gene Therapy Drugs; in Oncology; Table 46: Competitive Comparison of Target Profiles of Apoptotic Gene Therapy Based Drugs in Oncology; Table 47:Overview of the Competitive Landscape of Reformulated Apoptotic Drugs in Oncology; Table 48: Competitive Comparison of Target Profiles of Reformulated Apoptotic Drugs in Oncology; Table 49: The Competition Through Close Mechanistic Approximation Among All Apoptotic Drugs in Oncology; Table 50: Compound Strategies based on Sub-Cellular Localization of Apoptotic Drug Targets in Oncology; Table 51: Competitive Summary of Apoptotic Drugs by Cancer Indication; Table 52: Drug Target Profiles of Apoptotic Drugs for the Treatment of Acute Lymphocytic Leukemia; Table 53: Drug Target Profiles of Apoptotic Drugs for the Treatment of Acute Myelogenous Leukemia; Table 54: The Competition through Close Mechanistic Approximation between Acute Myelogenous Drugs; Table 55: Drug Target Profiles of Apoptotic Drugs for the Treatment of Adrenal Cancer; Table 56: Drug Target Profiles of Apoptotic Drugs for the Treatment of B-cell Lymphoma; Table 57: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs; Table 58: Drug Target Profiles of Apoptotic Drugs for the Treatment of Basal Cell Cancer; Table 59: Drug Target Profiles of Apoptotic Drugs for the Treatment of Biliary Cancer; Table 60: Drug Target Profiles of Apoptotic Drugs for the Treatment of Bladder Cancer; Table 61: Drug Target Profiles of Apoptotic Drugs for the Treatment of Bone Cancer; Table 62: Drug Target Profiles of Apoptotic Drugs for the Treatment of Brain Cancer; Table 63: Drug Target Profiles of Apoptotic Drugs for the Treatment of Breast Cancer; Table 64: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs; Table 65: Drug Target Profiles of Apoptotic Drugs for the Treatment of Carcinoid; Table of Contents 4; BioSeeker Group AB © 2009 | www.bioseeker.com 21; Table 66: Drug Target Profiles of Apoptotic Drugs for the Treatment of Cervical Cancer; Table 67: Drug Target Profiles of Apoptotic Drugs for the Treatment of Chronic Lymphocytic Leukemia; Table 68: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia; Drugs; Table 69: Drug Target Profiles of Apoptotic Drugs for the Treatment of Chronic Myelogenous Leukemia; Table 70: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia; Drugs; Table 71: Drug Target Profiles of Apoptotic Drugs for the Treatment of Colorectal Cancer; Table 72: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs; Table 73: Drug Target Profiles of Apoptotic Drugs for the Treatment of Endometrial Cancer; Table 74: Drug Target Profiles of Apoptotic Drugs for the Treatment of Ewing's Sarcoma; Table 75: Drug Target Profiles of Apoptotic Drugs for the Treatment of Fallopian Tube Cancer; Table 76: Drug Target Profiles of Apoptotic Drugs for the Treatment of Fibro Sarcoma; Table 77: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Cancer (general); Table 78: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stomach Cancer; Table 79: Drug Target Profiles of Apoptotic Drugs for the Treatment of Gastrointestinal Stromal Cancer; Table 80: Drug Target Profiles of Apoptotic Drugs for the Treatment of Head and Neck Cancer; Table 81: Drug Target Profiles of Apoptotic Drugs for the Treatment of Hodgkin's Lymphoma; Table 82: Drug Target Profiles of Apoptotic Drugs for the Treatment of Leiomyo Sarcoma; Table 83: Drug Target Profiles of Apoptotic Drugs for the Treatment of Leukemia (general); Table 84: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lipo Sarcoma; Table 85: Drug Target Profiles of Apoptotic Drugs for the Treatment of Liver Cancer; Table 86: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lung Cancer (general); Table 87: Drug Target Profiles of Apoptotic Drugs for the Treatment of Lymphoma (general); Table 88: Drug Target Profiles of Apoptotic Drugs for the Treatment of Melanoma; Table 89: The Competition through Close Mechanistic Approximation between Melanoma Cancer Drugs; Table 90: Drug Target Profiles of Apoptotic Drugs for the Treatment of Mesothelioma; Table 91: Drug Target Profiles of Apoptotic Drugs for the Treatment of Myelodysplastic Syndrome; Table 92: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs; Table 93: Drug Target Profiles of Apoptotic Drugs for the Treatment of Myeloma; Table 94: The Competition through Close Mechanistic Approximation between Myeloma Drugs; Table 95: Drug Target Profiles of Apoptotic Drugs for the Treatment of Nasopharyngeal Cancer; Table 96: Drug Target Profiles of Apoptotic Drugs for the Treatment of non-Hodgkin's Lymphoma; Table 97: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs; Table 98: Drug Target Profiles of Apoptotic Drugs for the Treatment of Non-Small Cell Lung Cancer; Table 99: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs; Table 100: Drug Target Profiles of Apoptotic Drugs for the Treatment of Oesophageal Cancer; Table 101: Drug Target Profiles of Apoptotic Drugs for the Treatment of Osteo Sarcoma; Table 102: Drug Target Profiles of Apoptotic Drugs for the Treatment of Ovarian Cancer; Table 103: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs; Table 104: Drug Target Profiles of Apoptotic Drugs for the Treatment of Pancreatic Cancer; Table 105: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs; Table 106: Drug Target Profiles of Apoptotic Drugs for the Treatment of Peritoneal Cancer; Table 107: Drug Target Profiles of Apoptotic Drugs for the Treatment of Prostate Cancer; Table 108: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs; Table 109: Drug Target Profiles of Apoptotic Drugs for the Treatment of Renal Cancer; Table 110: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs; Table 111: Drug Target Profiles of Apoptotic Drugs for the Treatment of Sarcoma (general); Table 112: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs; Table 113: Drug Target Profiles of Apoptotic Drugs for the Treatment of Small Cell Lung Cancer; Table 114: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs; Table 115: Drug Target Profiles of Apoptotic Drugs for the Treatment of Soft Tissue Sarcoma; Table 116: Drug Target Profiles of Apoptotic Drugs for the Treatment of Squamous Cell Cancer; Table 117: Drug Target Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma; Table 118: Drug Target Profiles of Apoptotic Drugs for the Treatment of T-cell Lymphoma; Table 119: Drug Target Profiles of Apoptotic Drugs for the Treatment of Testicular Cancer; Table 120: Drug Target Profiles of Apoptotic Drugs for the Treatment of Thymoma Cancer; Table 121: Drug Target Profiles of Apoptotic Drugs for the Treatment of Thyroid Cancer; Table 122: Drug Target Profiles of Apoptotic Drugs for the Treatment of Unspecified Cancer Indication; Table 123: The Competition through Close Mechanistic Approximation between Unspecified Cancer Indication Drugs; Table 124: Abbott's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 125: AbGenomics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 126: Access’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 127: Advanced Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 128: AEgera's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 129: Aeterna Zentaris’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 130: Aida Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 131: Ambrilia Biopharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 132: Amgen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 133: Anadys Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 472; Table 134: Anavex Life Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 135: Antisoma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 136: Aphios’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 137: Apogenix's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 138: ApopLogic Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 139: Arno Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 140: ArQule's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 141: Ascenta Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 142: Attenuon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 143: Basilea Pharmaceutica's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out . 501; Table 144: Bayer's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 145: BioAxone's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 146: Biogen Idec's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 147: BioInvent's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 148: BioLineRx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 149: Bionovo's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 150: BioVex's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 151: Cancer Research Technology's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 152: Cephalon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 153: ChemoCentryx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 154: Chlorogen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 155: Chroma Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 156: Cleveland BioLabs’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 157: CombinatoRx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 158: Coronado Biosciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 159: Critical Outcome Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 160: Curis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 161: Cyclacel's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 162: Cylene Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out . 546; Table 163: Cytochroma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 164: Daewoong's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 165: Daiichi Sankyo's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 166: Dainippon Sumitomo Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 167: Eisai's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 168: Eleos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 169: Eli Lilly's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 170: EntreMed's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 171: Enzon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 172: EpiCept's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 173: Exelixis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 174: Genentech's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 175: Genta's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 176: Genzyme's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 177: Gerolymatos’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 178: Geron's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 179: GlycoGenesys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 180: GPC Biotech's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 181: Hoffmann-La Roche's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 182: Hollis-Eden Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 183: Human Genome Sciences’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 184: Idera Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 185: Infinity Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 615; Table 186: InNexus Biotechnology's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out . 618; Table 187: Insmed's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 188: Intradigm's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 189: Introgen Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 190: Isis Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 191: ISU ABXIS’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 192: Johnson & Johnson's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 193: Kalypsys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 194: Keryx Biopharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 195: Kyowa Hakko Kirin's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 196: Lorus Therapeutics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 197: Medisyn Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 198: Merck & Co's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table of Contents 4; BioSeeker Group AB © 2009 | www.bioseeker.com 25; Table 199: MethylGene's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 200: NeoPharm's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 201: NIH's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 202: Nippon Shinyaku's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 203: Non-industrial source's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 204: Novacea's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 205: Novartis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 206: Novelix's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 207: Novogen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 208: Onconova's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 209: OSI Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 210: OXiGENE's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 211: PanaGin's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 212: Patrys’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 213: Pfizer's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 214: Pharmacyclics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 215: PharmaMar's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 216: Pharminox's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 217: Phytomedics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 218: Pierre Fabre's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 219: QLT's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 220: Reata Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out .. 713; Table 221: Regulon's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 222: Rosetta Genomics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 223: Sanofi-Aventis’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 224: Santaris Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 225: Semafore Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 226: Senesco Technologies’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 227: Sigma-Tau's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 228: SRI International's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 229: SuperGen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 230: Switch Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 231: Symbiotec's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 232: Taxolog's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 233: Telik's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; 4 Apoptotic Therapeutics In Oncology - Where to Commercialize?; 26 Cancer Highlights No 4 Vol 9 2009| BioSeeker Group AB © 2009; Table 234: Thallion Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 235: Tigris Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 236: TopoTarget's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 237: Tracon Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out 760; Table 238: Trubion's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 239: UMN Pharma's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 240: ValiRx's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 241: Vascular Biogenics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 242: Vertex Pharmaceuticals’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out . 772; Table 243: VioQuest's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 244: Viragen's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 245: Viralytics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 246: ViroTarg's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 247: VM Discovery's Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out; Table 248: ZymoGenetics’ Included Apoptotic Drug Pipeline in Oncology and Competitive Fall-Out

Apoptotic Therapeutics in Oncology - Where to Commercialize?

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service